Acute Ischemic Stroke Clinical Trial
Official title:
Acupuncture Intervention to Improve Neurological Function and Anti-inflammatory Effect in Patients With Acute Ischemic Stroke (ANAIS)
This study will have acupuncture intervention in acute ischemic stroke patients and evaluate the effect in neurological function improving by National Institutes of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), Barthel Index, and antiinflammatory actions by biomarkers.
Acupuncture Treatment in Stroke is a widely practiced in Taiwan, mainland China, and around
the world. The using in stroke group is countless. Numerous clinical trials have been
conducted in the medical community to assess efficacy, and the results mostly suggest that
acupuncture may be an effective, low side effects adjuvant therapy. Ischemic stroke is also
associated with chronic inflammation-related diseases. In recent years, the anti-inflammatory
effect of acupuncture was gradually found. So, whether in the basic or in clinical, the
investigators can deduce that acupuncture may be helpful for stroke as an adjuvant therapy.
This study evaluates the neurological function of patients with acute stroke by using the
widely used National Institutes of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS)
and Barthel Index. Also, the investigators assess the degree of inflammation by biomarkers.
Therefore, the purpose of this study is to explore the effect of acupuncture intervention on
acute ischemic patients and its relationship in anti-inflammatory actions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |